Paul J. Martin, M.D.


 Member, Fred Hutchinson Cancer Research Center 
Professor of Medicine, University of Washington 

Marquette University, Milwaukee, WI B.S. 1970 Biology 
University of Pennsylvania, Philadelphia, PA M.D. 1974 Medicine

 A. Personal Statement
My professional career at the University of Washington and Fred Hutchinson Cancer Research Center has been focused on clinical research related to hematopoietic cell transplantation, with a particular interest in clinical trials to prevent or treat acute and chronic graft-versus-host disease. This interest was exemplified by a review of adverse event reporting in clinical trials related to hematopoietic cell transplantation published in 2002 and by a report on clinical trial design published in 2006 as part of the NIH Consensus Conference on Criteria for Clinical Trials in Chronic GVHD. I served as P.I. of an R01-funded, investigator-initiated, IND-regulated multicenter, prospective double-blind phase III study to assess the efficacy of mycophenolate mofetil added to initial treatment for chronic GVHD. As a result of my work as Chair of the Guidelines Committee for the ASBMT, we published a critical review of the literature on primary and secondary treatment of acute GVHD in 2012. In 2013, I chaired a taskforce to develop recommendations to decrease the length of time between protocol release and protocol activation at centers participating in the Bone Marrow Transplant Clinical Trials Network. I was named as Medical Director for Clinical Research Support at the FHCRC in 2010. This office supports the conduct of cancer-related clinical trials by FHCRC and UW investigators. This support includes assistance with evaluation and selection of protocols to be opened, preparation and maintenance of regulatory files, data management. Clinical Research Support is also responsible for quality assurance and data and safety monitoring. As Medical Director, I serve as an ex-officio member of the Scientific Review Committee and the Protocol and Data Monitoring Committee. I also serve formally as the faculty liaison to the IRB. The FHCRC provides 40% salary support for me in this role.

B. Positions and Honors
7/74-6/75 Internship, Internal Medicine, Tufts New England Medical Center, Boston, Massachusetts
7/75-6/76 Residency, Internal Medicine, Tufts New England Medical Center, Boston Massachusetts
7/76-6/77 Residency, Internal Medicine, Case Western Reserve University Hospitals, Cleveland, Ohio
7/77-6/79 Fellowship, Oncology, University of Washington (UW) School of Medicine, Seattle, WA
7/79-6/81 Acting Instructor in Medicine, Division of Oncology, UW School of Medicine, Seattle, WA
7/79-1/82 Associate in Med Oncology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA
7/8l-1/82 Acting Assistant Professor of Medicine, Div. of Oncology, UW School of Medicine, Seattle, WA
2/82-6/85 Assistant Professor of Medicine, Division of Oncology, UW School of Medicine, Seattle, WA
2/82-6/85 Assistant Member, Division of Clinical Research, FHCRC
7/85-6/91 Associate Professor of Medicine, Division of Oncology, UW School of Medicine, Seattle, WA
7/85-6/91 Associate Member, Division of Clinical Research, FHCRC
7/91-present Professor of Medicine, Division of Oncology, UW School of Medicine, Seattle, WA
7/91-present Member, Division of Clinical Research, FHCRC
9/06-6/10 Member, Cancer Immunopathology and Immunotherapy Study Section, NIH
9/08-6/10 Chair, Cancer Immunopathology and Immunotherapy Study Section, NIH
2/07-2/10 Director, American Society of Blood and Marrow Transplantation
2012 E. Donnall Thomas Lecture, American Society of Blood and Marrow Transplantation
7/10-present Medical Director, Clinical Research Support, FHCRC
2/10-2/13 Vice Chair for North America, Advisory Committee; Center for International Blood and Marrow
Transplant Research (CIBMTR)
2/13-present Chair Elect, Advisory Committee, CIBMTR
7/13-present Associate Director for Clinical Research, Seattle Cancer Consortium
7/13-present Member, Scientific Board, National Patient Advocacy Foundation
11/13-present Member, Association of American Cancer Institutes Clinical Research Initiative Steering

C. Selected peer-reviewed publications (selected from more than 300 peer-reviewed publications)
1. Kansu E, Gooley T, Flowers MED, Anasetti C, Deeg J, Nash R, Sanders J, Witherspoon R, Appelbaum F,
Storb R, Martin P. Administration of cyclosporine for 24 months versus 6 months for prevention of chronic
graft-versus-host disease: a prospective randomized clinical trial. Blood 98:3868-70, 2001.
2. Flowers MED, Parker P, Johnston L, Matos AVB, Storer B, Bensinger WI, Storb R, Appelbaum FR, Forman
SJ, Blume KG, Martin PJ. Comparison of chronic graft-versus-host disease after transplantation of
peripheral blood stem cells versus bone marrow in allogeneic recipients: long term follow up of a
randomized trial. Blood 100:415-9, 2002.
3. Martin, P.J., Antin, J.H., Weisdorf, D.J., Paton, V., Horowitz, M.M. Reporting of adverse event data in
hematopoietic stem cell transplant clinical trials involving investigational new drugs or devices: A report
from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant 8: 295-302, 2002.
4. Koc S, Leisenring W, Flowers MED, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Storb
R, Appelbaum FR, Martin PJ. Therapy of chronic graft-versus-host disease: a randomized trial comparing
cyclosporine plus prednisone versus prednisone alone. Blood 100:48-51, 2002.
5. Syrjala KL, Langer SL, Abrams JR, Storer B, Sanders JE, Flowers MED, Martin PJ. Recovery and longterm
function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA 291:2335-43, 2004.
6. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ. Late effects of hematopoietic cell transplantation
among 10-year adult survivors compared with case-matched controls. J Clin Oncol 23:6596-606, 2005.
7. Martin,P.J., Weisdorf,D., Przepiorka,D., Hirschfeld,S., Farrell,A., Rizzo,J.D., Foley,R., Socie,G., Carter,S.,
Couriel,D., Schultz,K.R., Flowers,M.E.D., Filipovich,A.H., Saliba,R., Vogelsang,G.B., Pavletic,S.Z., Lee,S.J.
National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversus-
host disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 12:
491-505, 2006.
8. Martin,P.J., Storer,B.E., Rowley,S.D., Flowers,M.E.D., Lee,S.J., Carpenter,P.A., Wingard,J.R., Shaw,A.,
Devetten,M.P., Jagasia,M., Fay,J.W., van Besien,K., Gupta,V., Kitko,C., Johnston,L.J., Maziarz,R.T.,
Arora,M., Jacobson,P.A., Weisdorf,D. Evaluation of mycophenolate mofetil for initial treatment of chronic
graft-versus-host disease. Blood 113:5074-5082, 2009. PMCID: PMC2686178
9. Martin,P.J., Storer,B.E., Carpenter,P.A., Couriel,D.R., Flowers,M.E., Gupta,V., Hsu,J.W., Jagasia,M., Kitko,C.L., Maziarz,R.T., Rowley,S.D., Shaughnessy,P.J., van Besien,K., Weisdorf,D., Lee,S.J. Comparsion between short-term response and long-Term outcomes after initial systemic treatment of chronic graft-Versus-Host disease. Biol Blood Marrow Transplant 17: 124-32, 2010. PMCID: PMC2974028
10. Martin,P.J., Counts,G.W., Jr., Appelbaum,F.R., Lee,S.J., Sanders,J.E., Deeg,H.J., Flowers,M.E.D., Syrjala,K.L., Hansen,J.A., Storb,R.F., Storer,B.E. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 28: 1011-1016, 2010. PMCID: PMC2834427
11. Inamoto,Y., Flowers,M.E., Lee,S.J., Carpenter,P.A., Warren,E.H., Deeg,H.J., Storb,R.F., Appelbaum,F.R., Storer,B.E., Martin,P.J. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 118: 456-63, 2011. PMCID: PMC3138695
12. Palmer,J.M., Lee,S.J., Chai,X., Storer,B.E., Flowers,M.E.D., Schultz,K.R., Inamoto,Y., Cutler,C., Pidala,J., Arora,M., Jacobsohn,D.A., Carpenter,P.A., Pavletic,S.Z., Martin,P.J. Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-host Disease. BBMT 18:1649-55, 2012. PMCID: PMC3448865
13. Martin,P.J., Furlong,T., Rowley,S.D., Pergam,S.A., Lloid,M., Schubert,M.M., Horgan,K.J., Storer,B.E. Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-verus-host Disease. Biol Blood Marrow Transplant: 18: 922-929, 2012. PMCID: PMC3331897
14. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First and Second-Line Systemic Treatment of Acute Graft-versus-host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 18:1150-63, 2012. PMCID: PMC3404151
15. Inamoto Y, Storer BE, Lee SJ, Carpenter PA, Sandmaier BM, Flowers ME, Martin PJ. Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 121:2340-46, 2013. PMC3606068 [Available on 2014/3/21].

D. Research Support

Ongoing Research Support

R01 HL 105914-01 (P.I.: Hansen, J.) 1/10/2011 - 12/31/2014
Whole Genome Association Analysis of Hematopoietic Cell Transplant (HCT) Outcome
This project has 3 aims: Aim 1. Expand the currently available genome-wide SNP scans in HCT patient-donor pairs to achieve greater power for the discovery of genetic regions that influence the severity of the alloimmune response, and the risk of developing clinically important complications affecting morbidity and mortality. Aim 2. Perform an in silico candidate gene analysis of the expanded HCT cohort for associations with clinically significant transplant outcomes using gene-centric SNPs and other markers previously associated with HCT outcome and selected from among the SNPs compiled in the NIH GWAS Database from publications showing association with well-defined immune-mediated diseases. Aim 3. Develop an innovative approach to i) measuring genome-wide genetic disparity between donor and recipient, and using this measure to test for association with GVHD, relapse and mortality, and ii) identifying non-MHC loci encoding minor histocompatibility antigens that serve as the targets for GVHD and the graft-vs-leukemia (GVL) effect.

U01 CA118953-05 (P.I.: Lee) 7/18/2007 - 5/31/2017
Improving Outcomes Assessment in Chronic Graft vs. Host Disease
This project will follow 880 patients with chronic GVHD at four centers over a period of 5 years. Objective and subjective data regarding chronic GVHD disease activity, organ involvement, response to treatment, and impact on functional status and quality of life will be collected from patients and providers. These data will be used to test the recommendations of the recent NIH consensus conference on chronic GVHD.

U54 CA163438-04 (P.I.: Lee) 9/25/2009 - 8/31/2014
Immune Mediated Disorders after Allogeneic HCT
The goal of this Rare Diseases Clinical Research Consortium (RDCRC) is to advance our
understanding and treatment of acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Role: Co-Investigator.
Sub-Project: Administrative Core (Project Leader: Lee, S.J.)
Sub-Project: Core D (Project Leader: Martin, P.)
Long-term follow-up and chronic GVHD
Core D serves to collect long-term follow-up data and to provide guidance for management of chronic
GVHD and other complications after hematopoietic stem cell transplantation to treat nonmalignant
disorders, myelodysplastic syndromes, and myeloproliferative disorders.
Sub-Project: Pilot 1 (Project Leader: Martin, P.)
Biomarkers and Targeted Therapy of Bronchiolitis Obliterans
The goal of the Pilot/Demonstration Progam is to conduct early phase research studies what will
advance our knowledge about immune mediated disorders after allogeneic hematopoietic cell transplantation (HCT).

UL1 RR025015-05 (P.I.: Disis, N.) 9/17/2007-5/31/2013
Institute of Translational Health Sciences-subaward to FHCRC
The Institute of Translational Health Sciences represents a consortium of six University of Washington (UW) health science professional schools with multiple partners that cover 12 performance sites, involve 67 scientific key personnel and connect researchers to over 150 centers. In addition, the Institute of Translational Health Sciences proposes to integrate major research and clinical institutions across a five-state region: Washington, Wyoming, Alaska, Montana, and Idaho (WWAMI) via ongoing clinical and research collaboration pathways that are part of the WWAMI program led by the UW School of Medicine.
Sub-Project: Leadership Core (Project Leader: Martin, P.)
The ITHS will foster new health sciences interactions across the sites through a variety of technology, education, and research support cores. The Institute will guide, support and facilitate translational research efforts that focus on expanded information collection, sharing and analysis, innovative scientific technologies, and critical support services aimed at accelerating health sciences research.

CRA (P.I.: Martin, P.) 10/5/2011-9/30/2013
Regimmune Corporation
A Phase I, Open Label, MultiCenter, Dose Escalation Study to Evaluate the Safety and Tolerability of IV Administration of RGI-2001 in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation
This contract supports participation in an industry-sponsored multicenter clinical trial.

CRA (P.I.: Martin, P.) 7/22/2011-7/31/2013
Fresnius Biotech Corporation
A Randomized, Prospective, Double-Blind, Placebo-Controlled, Phase 3 Study of Study Drug Prophylaxis as a Supplement to Standard of Cadysplastic Syndrome Patients after Allogenic Hematopoietic Stem Cell Transplantation from Unrelated Donors
This contract supports participation in an industry-sponsored clinical trial.

P30 CA15704-39 (P.I.: Corey, L.) 1/1/1977 - 12/31/2015
Cancer Center Support Grant
The goal of the Fred Hutchinson/University of Washington Cancer Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. Dr. Martin serves as Associate Director for Clinical Research